Inhaled prostacyclin for term infants with persistent pulmonary hypertension refractory to inhaled nitric oxide

We report the use of inhaled prostacyclin (PGI2) in 4 neonates with persistent pulmonary hypertension and hypoxemia refractory to inhaled nitric oxide. Oxygenation rapidly improved after inhalation of PGI2 in all infants. The condition of one infant subsequently deteriorated, and alveolar capillary...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of pediatrics 2002-12, Vol.141 (6), p.830-832
Main Authors: Kelly, Lisa K., Porta, Nicolas F.M., Goodman, Denise M., Carroll, Christopher L., Steinhorn, Robin H.
Format: Article
Language:English
Subjects:
Administration, Inhalation
Antihypertensive Agents - administration & dosage
Antihypertensive Agents - therapeutic use
Biological and medical sciences
Epoprostenol - administration & dosage
Epoprostenol - therapeutic use
Humans
Infant, Newborn
Medical sciences
Nitric Oxide - administration & dosage
Nitric Oxide - therapeutic use
Persistent Fetal Circulation Syndrome - drug therapy
Pharmacology. Drug treatments
Respiratory system
Vasodilator Agents - administration & dosage
Vasodilator Agents - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We report the use of inhaled prostacyclin (PGI2) in 4 neonates with persistent pulmonary hypertension and hypoxemia refractory to inhaled nitric oxide. Oxygenation rapidly improved after inhalation of PGI2 in all infants. The condition of one infant subsequently deteriorated, and alveolar capillary dysplasia was found at autopsy. The surviving infants were discharged with normal oxygen saturations in room air. (J Pediatr 2002;141:830-32)
ISSN:0022-3476
1097-6833
DOI:10.1067/mpd.2002.129849